NEW YORK, March 2 (Reuters) - Genentech Inc (DNA.N) provided investors with earnings and revenue growth projections for every year through 2018 as it aimed to demonstrate that the company is worth more than Roche is willing to pay for it.
NEW YORK, March 2 (Reuters) - Genentech Inc (DNA.N) provided investors with earnings and revenue growth projections for every year through 2018 as it aimed to demonstrate that the company is worth more than Roche is willing to pay for it.
